Search the Newsreel

Assenagon Asset Management S.A. Acquires 4,334 Shares of Quest Diagnostics Incorporated $DGX

Assenagon Asset Management S.A. increased its stake in Quest Diagnostics Incorporated by 39.1% in the second quarter, acquiring 4,334 shares and bringing its total holdings to 15,405 shares valued at approximately $3.27 million. The medical research company reported strong Q2 earnings, exceeding estimates with …

Dimensional Fund Advisors LP Has $2.42 Million Stock Position in Magnera Corporation $MAGN

Dimensional Fund Advisors LP significantly increased its stake in Magnera Corporation (NYSE:MAGN) by 107.9% in the first quarter, now holding 253,908 shares valued at $2.42 million. Despite this, analyst sentiment remains cautious with an average "Reduce" rating and a consensus price target of $16. …

CLEO Diagnostics slips again as ovarian cancer test enters validation phase ahead of 2027 FDA filing

Latrobe Magnesium (ASX:LMG)Locks In Up To $16 Million To Chase First Magnesium Metal

Lumos Diagnostics Holdings (ASX:LDX)Turns FDA Clearance Into Sales as FebriDx Revenue Multiplies in the US

EKF Diagnostics tightens share base with latest buyback on AIM

Magnite, Inc. (NASDAQ:MGNI) Receives Average Rating of "Moderate Buy" from Brokerages

Magnite, Inc. (NASDAQ:MGNI) has received a "Moderate Buy" consensus rating from eleven brokerages, with nine analysts issuing a buy rating and two a hold. The average 12-month price target is $28.30, with recent upgrades from firms like Susquehanna and BTIG. The company also surpassed …

Krsnaa Diagnostics consolidated net profit declines 19.35% in the June 2026 quarter

KRSNAA: Q1 FY27 revenue up 22% YoY, retail surges 64%, but margins compress on higher fixed costs

Lucid Diagnostics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LUCD) 2026-08-13

Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Market Access Progress Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …

How Investors May Respond To Magnite (MGNI) Earnings Beat And Rising Profitability In CTV Advertising

Magnite reported strong Q2 2026 results with increased sales and net income, indicating improving profitability in its CTV advertising platform. This earnings beat reinforces the company's investment narrative, driven by the shift towards CTV and digital inventory, despite ongoing risks related to customer concentration …

Suraksha Diagnostic Ltd (NSE:SURAKSHA) (Q1 2027) Earnings Call Highlights: Strong 21% Revenue ...

Earnings Release: Here's Why Analysts Cut Their RHI Magnesita India Limited (NSE:RHIM) Price Target To ₹545

Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Quest Diagnostics Inc (DGX), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that DGX has a momentum score of 3.90, trading between resistance at $249.41 and support at $213.38. The …

Lucid Diagnostics (LUCD) Stock Slips As Lofty P S Meets Heavy Losses

Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6M

Earnings Call Insights: Co-Diagnostics (CODX) Q2 2026 MANAGEMENT VIEW * Dwight Egan (Chairman, CEO & President) framed Q2 as “another important step in our transition from platform development toward commercialization,” emphasizing “advancing regulatory milestones, expanding our global commercial opportunities, enhancing our platform capabilities and …

MGNI Stock Eyes Fourth Week Of Gains: Why This Analyst Thinks Magnite Still Has 26% Upside?

Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity

Co-Diagnostics (CODX) reported significant losses and minimal revenue for Q2 2026, leading management to flag substantial doubt about its ability to continue as a going concern without additional capital. The company posted a net loss of $6.3 million for the quarter and $15.4 million …

Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings

CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet

Co-Diagnostics (CODX) shares surged by nearly 80% on Tuesday, extending a six-session rally that has seen the stock climb over 630%. This surge is attributed to the company's expanded efforts to develop a PCR test for the Bundibugyo strain of the Ebola virus, amidst …

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $0.17 million and a net loss of $6.3 million. The company highlighted significant operational progress, including advancing manufacturing in Saudi Arabia, expanding commercial outreach in Europe and …

AGNC Investment Corp. (AGNC) Latest Stock News & Headlines

Magnum Ice Cream (NYSE:MICC) Sets New 12-Month High - Here's What Happened

KRSNAA: Revenue and profit rose, dividend declared, and warrants issued to promoters amid tax appeals

EKF Diagnostics Cancels 40,000 Shares in Targeted Buyback

Agnico-Eagle Mines Ltd. stock falls Thursday, underperforms market

Agnico-Eagle Mines Ltd. (AEM) shares dropped 2.44% on Thursday, closing at C$251.52. This performance underperformed the broader Canadian market, with the S&P/TSX Composite Index rising 0.26%. The stock is also 27.9% below its 52-week high of C$348.94 achieved on March 2nd.

Magnera Corp trades at a discount with strong earnings growth and deleveraging post-merger in nonwoven industry.

Magnera Corporation (MAGN), formed from the merger of Glatfelter and Berry's HHNF businesses, is successfully integrating operations, growing earnings, and reducing debt in the nonwoven industry. The company is currently undervalued, trading at 5.5x FY26E EBITDA compared to peers at 9x, with a free …

Needham reiterates Buy on Lucid Diagnostics stock, $3 target

Needham has reiterated a Buy rating and a $3.00 price target for Lucid Diagnostics Inc (NASDAQ:LUCD), citing potential upside from its current stock price of $0.97. The firm anticipates increased revenue growth as the company gains coverage for its EsoGuard test, especially with a …

Magnera (MAGN) Q3 2026 Earnings Call Transcript

Magnera (MAGN) reported a strong Q3 2026, with net sales increasing by 2% to $857 million and adjusted EBITDA up 9% to $99 million, driven by merger synergies and Project CORE initiatives. The company reaffirmed its full-year free cash flow guidance of $90 million …

Magnolia Beats Q2 Earnings on Higher Volumes and Price Realization

Magnolia Oil & Gas Corporation MGY reported a second-quarter 2026 net profit of 99 cents per share, which beat the Zacks Consensus Estimate of 90 cents. The bottom line more than doubled from the year-ago quarter's 43 cents. This outperformance can be attributed to …

Magnite director Rachel Lam sells $241,600 in company shares

Magnite director Rachel Lam sold 10,000 shares of Magnite, Inc. (NASDAQ:MGNI) stock on August 10, 2026, for a total of $241,600. This sale follows a 108% surge in Magnite shares over the past six months and strong Q2 2026 earnings, which led Scotiabank to …

Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates

Lucid Diagnostics Inc. (LUCD) reported a wider-than-expected Q2 loss of $0.06 per share, missing the Zacks Consensus Estimate of a $0.04 loss, and its revenues of $1.47 million also fell short of estimates. The company has underperformed the S&P 500 year-to-date, and its shares …

Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip

Lucid Diagnostics (LUCD) reported a Q2 2026 revenue beat of $1.47 million, surpassing expectations by 2.8%, though shares slipped slightly. The company matched Wall Street forecasts with a loss of 6 cents per share, and its EsoGuard test volume remained within target. Management highlighted …

Lucid Diagnostics earnings matched, revenue topped estimates

Lucid Diagnostics Non-GAAP EPS of -$0.06 misses by $0.01, revenue of $1.47M misses by $0.46M

* Lucid Diagnostics press release [https://seekingalpha.com/pr/20618076-lucid-diagnostics-provides-business-update-and-reports-second-quarter-2026-financial-results] (LUCD [https://seekingalpha.com/symbol/LUCD]): Q2 Non-GAAP EPS of -$0.06 misses by $0.01. * Revenue of $1.47M (+26.7% Y/Y) misses by $0.46M. * Processed 2,770 EsoGuard tests * Lucid had cash and cash equivalents of $33.4 million as of June 30, …

Lucid Diagnostics Secures EsoGuard Policy Adopted by Health Plans